Follow Us
https://www.thebody.com/author/joel-e-gallant

Joel E. Gallant, M.D., M.P.H.

Credit: MedPage Today via Joel Gallant

Dr. Gallant, one of the leading HIV specialists in the United States, is a professor of medicine and epidemiology in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine in Baltimore, Md., and professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health. He is also the associate director of the Johns Hopkins AIDS Service and director of the Garey Lambert Research Center, which conducts a wide range of clinical trials on HIV treatment.

In addition to caring for HIV-infected patients and directing a large HIV clinic, Dr. Gallant is actively involved in research on the natural history of HIV-associated opportunistic infections, as well as the treatment of HIV and its complications. He has authored or co-authored many research articles that have been published in major, peer-reviewed journals, and is a frequent presenter at the world's largest HIV/AIDS medical conferences. Dr. Gallant has also written a large number of HIV conference reports, as well as topical overviews of HIV medicine and disease management -- many of which appear in The Hopkins HIV Report, of which Dr. Gallant is the associate editor. He is also the editor of the Johns Hopkins HIV Guide, a web-based educational tool, and is on the editorial board of the Johns Hopkins AIDS Service Web site. Dr. Gallant and his colleague, the noted HIV researcher John G. Bartlett, M.D., are co-authors of Medical Management of HIV Infection, a respected, annually updated clinical guide.

Dr. Gallant earned his medical degree at the University of California-San Francisco School of Medicine before completing his residency at Yale-New Haven Hospital in Connecticut and his fellowship at the Johns Hopkins University School of Medicine. Dr. Gallant also holds a master's degree in public health, which he earned from the Johns Hopkins University School of Hygiene and Public Health. Dr. Gallant is a fellow in the Infectious Diseases Society of America and the American College of Physicians and is a member of the HIV Medical Association and the American Academy of HIV Medicine.

Disclosures

Dr. Gallant has received research support from Gilead Sciences, GlaxoSmithKline, Merck & Co., Pfizer, Inc., Roche Laboratories and Tibotec. He serves on advisory boards for Bristol-Myers Squibb, Gilead Sciences, Merck, Panacos Pharmaceuticals, Pfizer, Inc., Schering-Plough Corporation and Tibotec. He has been a consultant for Abbott Laboratories, GlaxoSmithKline and Vertex Pharmaceuticals. He serves on the data and safety monitoring board for Abbott, Gilead Sciences and Koronis Pharmaceuticals. In addition, he has received honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences and Tibotec.

Latest by Joel E. Gallant, M.D., M.P.H.

State of the Art: Expert Guidance on Choosing a Drug Regimen

State of the Art: Expert Guidance on Choosing a Drug Regimen

Joel Gallant, M.D., covers the basics of starting or switching an HIV drug regimen in this comprehensive review of treatment options.

Antiretroviral Therapy in 2016

Antiretroviral Therapy in 2016: Expert Guidance on Choosing a Drug Regimen

Joel Gallant, M.D., M.P.H., discusses his choices for initial therapy, options for simplification and switching and drugs in the pipeline.

The Role of Triumeq in HIV Treatment Img
News

The Role of Triumeq in HIV Treatment

"There's a growing recognition ... that starting therapy with integrase inhibitors may be the best way to go for most people, and there are now two integrase inhibitor-based STRs to choose from: Stribild and Triumeq," writes leading HIV physician Joe...

Antiretroviral Therapy in 2014: How Does a Doctor Choose? Img
News

Antiretroviral Therapy in 2014: How Does a Doctor Choose?

Today, there are more treatment options than ever before for a person newly diagnosed with HIV. How does a doctor choose?

Promo Image

Class Distinction

All antiretroviral drugs work in essentially the same way -- by preventing the virus from replicating. They're classified based on the stage of the HIV life cycle they target. Most antiretroviral regimens include drugs from at least two of the six cl...

Promo Image

100 Questions & Answers About HIV and AIDS -- Part 6: Starting Treatment

An excerpt from 100 Questions & Answers About HIV and AIDS, published by Jones and Bartlett Publishers, 2008. To purchase this book, click here. To read or listen to an interview with Dr. Gallant, click here.

Joel E. Gallant, M.D., 100 Questions & A...

Promo Image

100 Questions & Answers About HIV and AIDS

An excerpt from 100 Questions & Answers About HIV and AIDS, published by Jones and Bartlett Publishers, 2008. To purchase this book, click here. To read or listen to an interview with Dr. Gallant, click here.

Joel E. Gallant, M.D., 100 Questions & A...

Promo Image
Health Coverage

100 Questions & Answers About HIV and AIDS -- Part 4: Medical Care

An excerpt from 100 Questions & Answers About HIV and AIDS, published by Jones and Bartlett Publishers, 2008. To purchase this book, click here. To read or listen to an interview with Dr. Gallant, click here.

Joel E. Gallant, M.D., 100 Questions & A...

Q&A: Ask the Experts

Hydroxyurea & Hair Loss

Dear Dr. Gallant -- Is it true that hair loss can occur with Hydroxyurea? And if so, what are the chances of it? Does the hair return? Also, what percentage of people have low white cell counts from it? Mine is at 3.8 -- Thanks very much.

Q&A: Ask the Experts

Folliculitis

Doctors, Can you tell me if there is a standardized first line treatment for eosinophilic folliculitis? I understand that the cause is not well understood (bacterial, fungal, etc.), so where does one start? I've seen excellent results with Acutane an...